Core Insights - Corcept Therapeutics announced data from the phase II DAZALS study evaluating dazucorilant for treating amyotrophic lateral sclerosis (ALS) [1] - The study did not meet its primary endpoint, leading to a decline in Corcept's shares in pre-market trading [2] - Year-to-date, Corcept's shares have increased by 85%, contrasting with a 4.6% decline in the industry [3] Study Details - The DAZALS study was a double-blind, placebo-controlled trial assessing two doses of dazucorilant (150 mg and 300 mg) [1] - Patients treated with dazucorilant experienced significantly more gastrointestinal upset compared to the placebo group [4] - An open-label, long-term extension study will continue, with overall survival data expected in March next year [5] Regulatory and Pipeline Updates - The FDA has granted Fast Track Designation to dazucorilant for ALS treatment [7] - Corcept's lead pipeline candidate, relacorilant, is in phase III of the GRACE study for Cushing's syndrome [8] - An NDA for relacorilant in Cushing's syndrome is anticipated to be submitted shortly [10] Additional Studies - Relacorilant is also being evaluated in combination with other drugs for various cancer indications, including a phase III study for platinum-resistant ovarian cancer [11]

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Sco ...

A month has gone by since the last earnings report for Corcept Therapeutics (CORT) . Shares have added about 19.7% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Corcept due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. Corcept Beats Q3 Earnings & Sales Estimates, ...

Welcome to my profile!My name is Vincent. I have over three years of experience as a tech-oriented buy-side analyst at a major bank, where I co-managed U.S. equity portfolios with over $700M in assets under management. I’ve worked across both large-cap and small-cap stocks, gaining a deep understanding of financial markets. Fascinated by innovation and its potential, my goal is not only to identify tomorrow's future leaders but also to share and discuss these insights with you.I believe every investor shoul ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? The Za ...

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock.That's because, these stocks usually carry above-average risk and volatility. In fact, betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss.However, it's pretty easy to find cutting-edge growth stocks with the help of the Zacks Gro ...

Corcept Therapeutics (CORT) closed the last trading session at $54.31, gaining 11% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $74.90 indicates a 37.9% upside potential.The mean estimate comprises five short-term price targets with a standard deviation of $5.03. While the lowest estimate of $67 indicates a 23.4% increase from the current price level, the most optimistic analyst ...

Core Viewpoint - The article emphasizes the importance of confirming the sustainability of stock trends for profitable short-term investing, highlighting that trends can reverse unexpectedly, leading to potential losses for investors [1][2]. Group 1: Stock Performance - Corcept Therapeutics (CORT) has shown a solid price increase of 56.7% over the past 12 weeks, indicating strong investor interest and potential upside [4]. - CORT has also experienced an 11% price increase over the last four weeks, suggesting that the upward trend is still intact [5]. - The stock is currently trading at 82% of its 52-week high-low range, indicating it may be on the verge of a breakout [5]. Group 2: Fundamental Strength - CORT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, which are critical for near-term price movements [6]. - The stock has an Average Broker Recommendation of 1 (Strong Buy), reflecting high optimism from the brokerage community regarding its near-term price performance [7]. Group 3: Investment Strategy - The article suggests using the "Recent Price Strength" screen to identify stocks like CORT that are on an uptrend supported by strong fundamentals [3]. - It mentions that there are over 45 Zacks Premium Screens available for investors to find stocks that align with their personal investing styles [8].

Industry Overview - The drug industry is anticipating a shift in policy with Donald Trump's reelection, potentially leading to increased innovation and M&A activity, while efforts to repeal the Inflation Reduction Act (IRA) are likely [1][2] - Drug pricing reforms will remain a priority for the new government, with previous emphasis on controlling drug prices during Trump's last term [2] - The Zacks Medical-Drugs industry is showing promising trends in 2024, driven by increased M&A and positive pipeline developments, particularly in diabetes/obesity, inflammation, and neuroscience [3] Company Highlights - **Corcept Therapeutics**: The company’s sole marketed drug, Korlym, has seen strong demand, leading to an increase in annual revenue guidance. The stock has risen 67.2% this year, with 2024 earnings estimates increasing from $1.12 to $1.31 per share [15][16] - **Madrigal Pharmaceuticals**: The FDA approved Rezdiffra, the first therapy for noncirrhotic NASH, generating approximately $77 million in sales since its launch. The stock is up 53.4% this year, with loss estimates improving from $29.49 to $24.08 per share [17][18] - **Catalyst Pharmaceuticals**: The lead drug Firdapse is experiencing strong demand, and the company has diversified its portfolio with the acquisition of Fycompa. The stock has risen 38.3% this year, with stable earnings estimates at $1.92 per share [19][20] - **Theravance Biopharma**: The company is benefiting from increased collaboration revenues from its product Yupelri. However, the stock has declined 22.1% this year, with stable loss estimates at 45 cents per share [21][23] - **Larimar Therapeutics**: The company is developing nomlabofusp for Friedreich's ataxia, with a significant stock increase of 100.5% over the past year. Loss estimates have narrowed from $1.39 to $1.16 per share [24][26] Market Performance - The Zacks Medical-Drugs industry has underperformed the S&P 500 and the broader Medical sector, with a year-to-date decline of 3.4% compared to the S&P 500's increase of 24.7% [13] - The industry currently trades at a price-to-sales ratio of 2.24, significantly lower than the S&P 500's 6.19 and the Zacks Medical sector's 3.44 [14]

The drug industry witnessed major policy changes during Joe Biden's four-year term as U.S. President, including the historic Inflation Reduction Act (“IRA”). With Donald Trump’s reelection, the biotech industry hopes to witness more innovation and mergers and acquisitions (M&A) activity. Efforts to repeal the IRA look likely. However, it all depends on who is appointed to key roles at federal health agencies. Drug pricing reforms are expected to remain a key priority for the new government. Trump, in his pr ...